TABLE OF CONTENTS
1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.3 OVERVIEW OF THE EUROPE GASTRIC CANCER DIAGNOSTICS MARKET 47
1.4 LIMITATIONS 50
1.5 MARKETS COVERED 50
2 MARKET SEGMENTATION 53
2.1 MARKETS COVERED 53
2.2 GEOGRAPHICAL SCOPE 54
2.3 YEARS CONSIDERED FOR THE STUDY 55
2.4 CURRENCY AND PRICING 55
2.5 DBMR TRIPOD DATA VALIDATION MODEL 56
2.6 MULTIVARIATE MODELLING 59
2.7 PRODUCT TYPE LIFELINE CURVE 59
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.9 DBMR MARKET POSITION GRID 61
2.10 VENDOR SHARE ANALYSIS 62
2.11 MARKET END COVERAGE GRID 63
2.12 SECONDARY SOURCES 64
2.13 ASSUMPTIONS 64
3 EXECUTIVE SUMMARY 65
4 PREMIUM INSIGHT 68
4.1 PESTEL'S MODEL 69
4.2 PORTER'S 5 FORCES 70
4.3 EPIDEMIOLOGY 71
4.4 BRAND ANALYSIS 72
4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): EUROPE GASTRIC CANCER DIAGNOSTICS MARKET 76
4.6 INDUSTRY INSIGHTS: 78
5 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY 79
5.1 EUROPEAN UNION (EU)- 79
6 MARKET OVERVIEW 81
6.1 DRIVERS 83
6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA 83
6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING 83
6.1.3 INCREASE IN THE GERIATRIC POPULATION 84
6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS 84
6.2 RESTRAINTS 85
6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST 85
6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES 85
6.3 OPPORTUNITIES 86
6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS 86
6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS 86
6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS 87
6.4 CHALLENGES 88
6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES 88
6.4.2 LIMITATIONS OF RADIATION TESTS 88
7 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 89
7.1 OVERVIEW 90
7.2 REAGENTS & CONSUMABLES 93
7.2.1 KITS 94
7.2.1.1 DNA POLYMERASE KITS 94
7.2.1.2 PCR KITS 94
7.2.1.3 NUCLEIC ACID ISOLATION KITS 94
7.2.1.4 OTHERS 94
7.2.2 REAGENTS 95
7.2.2.1 ASSAYS 95
7.2.2.2 BUFFERS 95
7.2.2.3 PRIMERS 95
7.2.2.4 OTHERS 95
7.3 INSTRUMENTS 96
7.4 SERVICES 97
8 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 98
8.1 OVERVIEW 99
8.2 CONFIRMATORY TEST 102
8.2.1 IMAGING TESTS 103
8.2.1.1 PET SCAN/CT SCAN 103
8.2.1.2 CT SCAN 103
8.2.1.3 ULTRASOUND 103
8.2.1.4 MRI 104
8.2.1.5 X-RAY 104
8.2.2 BIOMARKER 104
8.2.2.1 DNA BIOMARKER 104
8.2.2.2 RNA BIOMARKER 104
8.2.2.3 PROTEIN BIOMARKER 104
8.2.3 BIOPSY 104
8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM 105
9 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP 106
9.1 OVERVIEW 107
9.2 GERIATRICS 110
9.3 ADULT 111
9.4 PEDIATRIC 112
10 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE 113
10.1 OVERVIEW 114
10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA 117
10.3 CARCINOID TUMOR 118
10.4 GASTROINTESTINAL STROMAL TUMOR 119
10.5 GASTRIC LYMPHOMA 120
10.6 OTHERS 121
11 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE 122
11.1 OVERVIEW 123
11.2 STAGE I 126
11.2.1 STAGE IA 127
11.2.2 STAGE IB 127
11.3 STAGE II 127
11.3.1 STAGE IIA 128
11.3.2 STAGE IIB 128
11.4 STAGE III 128
11.4.1 STAGE IIIA 129
11.4.2 STAGE IIIB 130
11.4.3 STAGE IIIC 130
11.5 STAGE 0 130
12 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER 131
12.1 OVERVIEW 132
12.2 MALE 135
12.3 FEMALE 136
13 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE 137
13.1 OVERVIEW 138
13.2 STOOL 141
13.3 TISSUE 142
13.4 BLOOD 143
13.5 URINE 144
14 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER 145
14.1 OVERVIEW 146
14.2 HOSPITALS 149
14.3 DIAGNOSTIC LABORATORIES 150
14.4 CANCER RESEARCH INSTITUTES 151
14.5 ONCOLOGY SPECIALTY CLINICS 152
14.6 OTHERS 153
15 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 154
15.1 OVERVIEW 155
15.2 DIRECT TENDERS 158
15.3 RETAIL SALES 159
16 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION 160
16.1 EUROPE 161
16.1.1 GERMANY 172
16.1.2 FRANCE 177
16.1.3 U.K 182
16.1.4 RUSSIA 187
16.1.5 ITALY 192
16.1.6 SPAIN 197
16.1.7 BELGIUM 202
16.1.8 NETHERLANDS 207
16.1.9 TURKEY 212
16.1.10 SWITZERLAND 217
16.1.11 REST OF EUROPE 222
17 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 223
17.1 COMPANY SHARE ANALYSIS: EUROPE 223
18 SWOT ANALYSIS 224
19 COMPANY PROFILE 225
19.1 F. HOFFMANN-LA ROCHE LTD 225
19.1.1 COMPANY SNAPSHOT 225
19.1.2 REVENUE ANALYSIS 225
19.1.3 COMPANY SHARE ANALYSIS 226
19.1.4 PRODUCT PORTFOLIO 226
19.1.5 RECENT DEVELOPMENT 226
19.2 GENERAL ELECTRIC 227
19.2.1 COMPANY SNAPSHOT 227
19.2.2 REVENUE ANALYSIS 227
19.2.3 COMPANY SHARE ANALYSIS 228
19.2.4 PRODUCT PORTFOLIO 228
19.2.5 RECENT DEVELOPMENT 228
19.3 ABBOTT 229
19.3.1 COMPANY SNAPSHOT 229
19.3.2 REVENUE ANALYSIS 229
19.3.3 COMPANY SHARE ANALYSIS 230
19.3.4 PRODUCT PORTFOLIO 230
19.3.5 RECENT DEVELOPMENT 230
19.4 QIAGEN 231
19.4.1 COMPANY SNAPSHOT 231
19.4.2 REVENUE ANALYSIS 231
19.4.3 COMPANY SHARE ANALYSIS 232
19.4.4 PRODUCT PORTFOLIO 232
19.4.5 RECENT DEVELOPMENT 232
19.5 MYRIAD GENETICS, INC. 233
19.5.1 COMPANY SNAPSHOT 233
19.5.2 REVENUE ANALYSIS 233
19.5.3 COMPANY SHARE ANALYSIS 234
19.5.4 PRODUCT PORTFOLIO 234
19.5.5 RECENT DEVELOPMENT 234
19.6 ACON LABORATORIES, INC. 235
19.6.1 COMPANY SNAPSHOT 235
19.6.2 PRODUCT PORTFOLIO 235
19.6.3 RECENT DEVELOPMENT 235
19.7 ADVACARE PHARMA 236
19.7.1 COMPANY SNAPSHOT 236
19.7.2 PRODUCT PORTFOLIO 236
19.7.3 RECENT DEVELOPMENT 236
19.8 AGILENT TECHNOLOGIES, INC. 237
19.8.1 COMPANY SNAPSHOT 237
19.8.2 REVENUE ANALYSIS 237
19.8.3 PRODUCT PORTFOLIO 238
19.8.4 RECENT DEVELOPMENTS 238
19.9 BIOMRIEUX 239
19.9.1 COMPANY SNAPSHOT 239
19.9.2 REVENUE ANALYSIS 239
19.9.3 PRODUCT PORTFOLIO 240
19.9.4 RECENT DEVELOPMENT 240
19.10 BIOCEPT, INC. 241
19.10.1 COMPANY SNAPSHOT 241
19.10.2 REVENUE ANALYSIS 241
19.10.3 PRODUCT PORTFOLIO 242
19.10.4 RECENT DEVELOPMENT 242
19.11 BIOHIT OYJ 243
19.11.1 COMPANY SNAPSHOT 243
19.11.2 REVENUE ANALYSIS 243
19.11.3 PRODUCT PORTFOLIO 244
19.11.4 RECENT DEVELOPMENT 244
19.12 DIASORIN S.P.A 245
19.12.1 COMPANY SNAPSHOT 245
19.12.2 REVENUE ANALYSIS 245
19.12.3 PRODUCT PORTFOLIO 246
19.12.4 RECENT DEVELOPMENT 246
19.13 ENDOFOTONICS PTE LTD 247
19.13.1 COMPANY SNAPSHOT 247
19.13.2 PRODUCT PORTFOLIO 247
19.13.3 RECENT DEVELOPMENT 247
19.14 FOUNDATION MEDICINE, INC. 248
19.14.1 COMPANY SNAPSHOT 248
19.14.2 PRODUCT PORTFOLIO 248
19.14.3 RECENT DEVELOPMENTS 248
19.15 FUJIREBIO (AN H.U. GROUP COMPANY) 249
19.15.1 COMPANY SNAPSHOT 249
19.15.2 REVENUE ANALYSIS 249
19.15.3 PRODUCT PORTFOLIO 250
19.15.4 RECENT DEVELOPMENT 250
19.16 MIRXES PTE LTD. 251
19.16.1 COMPANY SNAPSHOT 251
19.16.2 PRODUCT PORTFOLIO 251
19.16.3 RECENT DEVELOPMENT 251
19.17 PARAGON GENOMICS, INC. 252
19.17.1 COMPANY SNAPSHOT 252
19.17.2 PRODUCT PORTFOLIO 252
19.17.3 RECENT DEVELOPMENTS 252
19.18 TECO DIAGNOSTICS 253
19.18.1 COMPANY SNAPSHOT 253
19.18.2 PRODUCT PORTFOLIO 253
19.18.3 RECENT DEVELOPMENT 253
19.19 THERMO FISHER SCIENTIFIC INC. 254
19.19.1 COMPANY SNAPSHOT 254
19.19.2 REVENUE ANALYSIS 254
19.19.3 PRODUCT PORTFOLIO 255
19.19.4 RECENT DEVELOPMENTS 255
19.20 VELA DIAGNOSTICS 256
19.20.1 COMPANY SNAPSHOT 256
19.20.2 PRODUCT PORTFOLIO 256
19.20.3 RECENT DEVELOPMENTS 256
20 QUESTIONNAIRE 257
21 RELATED REPORTS 262

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.